JSJonathan Sales

Jonathan Sales

*This is an algorithmically generated author record based on publicly available information.

Jonathan Sales has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Superior Outcomes for a Novel Cervical Disc Replacement Compared With Anterior Cervical Discectomy and Fusion: Two-Year Results from a Prospective IDE Study With Propensity-Matched Historical Control

    by David Musante, Todd Lanman, Daniel Peterson, Adam Bruggeman, Jared Ament, Ashvin Patel, Rick Sasso, J. Rafe Sales, Daniel Park, Jad Khalil, et al.

    Study Design: Prospective, multicenter, study with a propensity-matched historical control conducted under a US FDA IDE. Objective: To evaluate the safety and efficacy of the synergy disc (SD) compared to anterior cervical discectomy and fusion (ACDF) for single-level symptomatic cervical disc disease. Summary of Background Data: Cervical disc replacement (CDR) was developed to preserve motion while achieving outcomes comparable to ACDF. Although currently available devices are designed primarily to maintain motion, the SD is designed to provide intentional motion and restore segmental lordosis to help optimize sagittal balance. The disc is composed of titanium endplates that articulate with an ultra-high molecular weight polyethylene core with either 0 or 6° of lordosis. Materials and Methods: Adults with cervical radiculopathy or myelopathy at a single level and qualifying pain (VAS) and disability scores (NDI) were enrolled. The primary study endpoint was individual composite clinical success (CCS) at 24 months. CCS was achieved if a subject met the following criteria: at least a 15-point improvement in NDI score, maintenance/improvement in neurological status, and absence of the following: secondary surgical intervention on the index level, radiographic failure, and device-related serious adverse events. Secondary endpoints include change from baseline on patient-reported outcomes and treatment satisfaction. Results: One hundred seventy-seven patients were enrolled in the CDR group across 20 US sites; data on 192 control subjects were available. The study achieved success for both noninferiority and superiority at the two-year primary endpoint ( P <0.0001). At two years, 87.1% in the CDR group and 56.6% in the control group met CCS success. The CDR group demonstrated greater improvements in pain and function across all time points. Significant increases in segmental and regional alignment were observed in the CDR group. Conclusions: Two-year primary endpoint results support the safety and efficacy of a CDR that incorporates motion and lordosis. Clinical success results were superior to ACDF.

  • Open Access

    Twelve-Month Results from a Prospective Clinical Study Evaluating the Efficacy and Safety of Cellular Bone Allograft in Subjects Undergoing Lumbar Spinal Fusion

    by Joshua Wind, Daniel Park, Todd Lansford, Pierce Nunley, Timothy Peppers, Anthony Russo, Hamid Hassanzadeh, Jonathan N. Sembrano, Jung Yoo, Jonathan Sales

    Background: While autologous bone grafts remain the gold standard for spinal fusion procedures, harvesting autologous bone is associated with significant complications, including donor site infection, hematomas, increased operative time, and prolonged pain. Cellular bone allograft (CBA) presents an alternative to autologous bone harvesting, with a favorable efficacy and safety profile. The current study further investigates CBA as an adjunct to lumbar spinal fusion procedures. Methods: A prospective, multicenter, open-label clinical study was conducted in subjects undergoing lumbar spinal fusion with CBA (NCT 02969616). Radiographic fusion status was assessed by an independent review of dynamic radiographs and CT scans. Clinical outcome measures included the Oswestry Disability Index (ODI) and visual analogue scale (VAS) for back and leg pain. Adverse-event reporting was conducted throughout 12 months of follow-up. Available subject data at 12 months were analyzed. Results: A total of 274 subjects were enrolled into the study, with available data from 201 subjects (73.3%) who completed 12 months of postoperative radiographic and clinical evaluation at the time of analysis. Subjects had a mean age of 60.2 ± 11.5 years. A higher number of women (n = 124, 61.7%) than men (n = 77, 38.3%) were enrolled, with a collective mean BMI of 30.6 + 6.5 kg/m2 (range 18.0–51.4). At month 12, successful fusion was achieved in 90.5% of subjects. A significant (p < 0.001) improvement in ODI, VAS-back, and VAS-leg clinical outcomes was also observed compared to baseline scores. One adverse event related to CBA (postoperative radiculopathy) was reported, with surgical exploration demonstrating interbody extrusion of graft material. This subject reported successful fusion at month 12. Conclusions: CBA represents a viable substitute for harvesting of autograft alone with a high rate of successful fusion and significant improvements in subject-reported outcomes, such as pain and disability. Positive benefit was observed in subjects reporting single and multiple risk factors for pseudoarthrosis.